Canopy Immuno-Therapeutics
Immunotherapeutic Approach for Autoimmunity and Life-threatening Allergies
Company Overview
Snapshot
Founded in December 2019 by Kfir Oved, Canopy Immuno-Therapeutics operates with 1–10 employees. The company has secured funding across two rounds. In December 2019, Canopy Immuno-Therapeutics received its initial funding from.
Business overview
Canopy Immuno-Therapeutics is a preclinical-stage biotech company developing a new class of biologics designed to eliminate antigen-specific immunity. Utilizing its proprietary Reverse-Immunization platform, the company aims to provide non-immunosuppressive, potentially curative treatments for a wide range of autoimmune, allergic, and other antibody-mediated conditions. Operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, Canopy Immuno-Therapeutics serves the global market with a focus on biotechnology.
Strategic signal
In November 2020, research co-authored by Canopy Immuno-Therapeutics' founder was published in The Lancet, detailing a multi-center nationwide comparison of seven serology assays that revealed a SARS-CoV-2 non-responding seronegative subpopulation. This publication highlights the scientific rigor and research capabilities within the company's leadership, providing a strong signal of its foundational expertise in immunology and its potential to contribute to significant medical advancements.
Log in to access full profile ›Company Intelligence Q&A
- When was Canopy Immuno-Therapeutics founded?
- Canopy Immuno-Therapeutics was founded in December 2019 by Kfir Oved.
- What is Canopy Immuno-Therapeutics' primary focus?
- Canopy Immuno-Therapeutics is focused on developing a new class of biologics using its proprietary Reverse-Immunization platform to eliminate antigen-specific immunity, aiming for non-immunosuppressive treatments for autoimmune, allergic, and antibody-mediated conditions.
- Which investor participated in Canopy Immuno-Therapeutics' funding round?
- In December 2019, TLV Partners participated in a funding round for Canopy Immuno-Therapeutics.
- What significant research was published by a founder of Canopy Immuno-Therapeutics?
- In November 2020, research co-authored by a founder of Canopy Immuno-Therapeutics was published in The Lancet, focusing on a multi-center nationwide comparison of seven serology assays that identified a SARS-CoV-2 non-responding seronegative subpopulation.
- What is the current product stage of Canopy Immuno-Therapeutics?
- Canopy Immuno-Therapeutics is currently in the R&D stage for its products, including the Reverse-Immunization platform.